JP2005502680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502680A5 JP2005502680A5 JP2003524596A JP2003524596A JP2005502680A5 JP 2005502680 A5 JP2005502680 A5 JP 2005502680A5 JP 2003524596 A JP2003524596 A JP 2003524596A JP 2003524596 A JP2003524596 A JP 2003524596A JP 2005502680 A5 JP2005502680 A5 JP 2005502680A5
- Authority
- JP
- Japan
- Prior art keywords
- dementia
- galantamine
- topiramate
- use according
- result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 28
- 206010012289 Dementia Diseases 0.000 claims 22
- 229960003980 galantamine Drugs 0.000 claims 14
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 14
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 12
- 229960004394 topiramate Drugs 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 8
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 4
- 206010027175 memory impairment Diseases 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
- 125000002009 alkene group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 229960003530 donepezil Drugs 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- -1 methylenedioxy group Chemical group 0.000 claims 2
- 229960001952 metrifonate Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229960004136 rivastigmine Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960001685 tacrine Drugs 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 208000012184 Diffuse Brain injury Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31597801P | 2001-08-30 | 2001-08-30 | |
| PCT/US2002/027504 WO2003020289A1 (en) | 2001-08-30 | 2002-08-28 | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502680A JP2005502680A (ja) | 2005-01-27 |
| JP2005502680A5 true JP2005502680A5 (https=) | 2006-01-05 |
Family
ID=23226936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524596A Pending JP2005502680A (ja) | 2001-08-30 | 2002-08-28 | 抗痙攣剤およびアセチルコリンエステラーゼ阻害剤による痴呆および記憶障害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030060423A1 (https=) |
| EP (1) | EP1423127A1 (https=) |
| JP (1) | JP2005502680A (https=) |
| CA (1) | CA2459146A1 (https=) |
| MX (1) | MXPA04001959A (https=) |
| WO (1) | WO2003020289A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| GB0405034D0 (en) * | 2004-03-05 | 2004-04-07 | Novartis Ag | Organic compounds |
| HRP20060326A2 (hr) * | 2004-03-12 | 2007-02-28 | Egis Gy�gyszergy�r Nyrt. | Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5237112B2 (ja) * | 2006-12-01 | 2013-07-17 | 日東電工株式会社 | 経皮吸収製剤 |
| US20100048628A1 (en) * | 2006-12-01 | 2010-02-25 | Sumiyo Nishi | Method for suppressing discoloration over time of adhesive preparation containing donepezil |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| WO2009145177A1 (ja) * | 2008-05-30 | 2009-12-03 | 日東電工株式会社 | ドネペジル含有貼付製剤およびその包装体 |
| KR20110020788A (ko) * | 2008-05-30 | 2011-03-03 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 경피 흡수 제제 |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2011143721A1 (en) * | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US12208167B1 (en) * | 2024-02-06 | 2025-01-28 | Alpha Cognition Inc. | Coated tablets for pH-dependent release of benzgalantamine |
| US12551491B1 (en) | 2025-07-23 | 2026-02-17 | Alpha Cognition Inc. | Dosage regimens for benzgalantamine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| AU3501697A (en) * | 1996-06-28 | 1998-01-21 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
| US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| FR2757512B1 (fr) * | 1996-12-24 | 1999-03-12 | Sanofi Sa | Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines |
| US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| HUP0101299A3 (en) * | 1998-12-03 | 2002-04-29 | Ortho Mcneil Pharm Inc | Use of topiramate and derivatives for manufacturing medicament useful for treating schizophrenia |
| WO2000061138A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| US6486198B1 (en) * | 1999-05-28 | 2002-11-26 | Jeffrey Berlant | Compounds and methods for the treatment of post traumatic stress disorder |
| EP1311272B1 (en) * | 2000-03-03 | 2006-11-22 | Eisai Co., Ltd. | Novel methods using cholinesterase inhibitors |
| EP1309325A1 (en) * | 2000-08-02 | 2003-05-14 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| DK1471871T3 (da) * | 2001-02-02 | 2007-09-17 | Ortho Mcneil Pharm Inc | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
| US6821979B2 (en) * | 2002-03-07 | 2004-11-23 | Blanchette Rockefeller Neurosciences Institute | Synergistic enhancement of cognitive ability |
-
2002
- 2002-08-28 CA CA002459146A patent/CA2459146A1/en not_active Abandoned
- 2002-08-28 EP EP02757450A patent/EP1423127A1/en not_active Withdrawn
- 2002-08-28 MX MXPA04001959A patent/MXPA04001959A/es not_active Application Discontinuation
- 2002-08-28 JP JP2003524596A patent/JP2005502680A/ja active Pending
- 2002-08-28 US US10/229,878 patent/US20030060423A1/en not_active Abandoned
- 2002-08-28 WO PCT/US2002/027504 patent/WO2003020289A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502680A5 (https=) | ||
| JP2002517467A5 (https=) | ||
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| JP2006507220A5 (https=) | ||
| JPS62249923A (ja) | パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法 | |
| CA2284732A1 (en) | Analogs of cocaine | |
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| AU9189301A (en) | Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments | |
| HUT59313A (en) | Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions | |
| WO2001085145A3 (en) | A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| MXPA02008770A (es) | Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina. | |
| CA2438991A1 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| CA2468649A1 (en) | Adenosine a2a receptor antagonists | |
| AP2002002465A0 (en) | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders. | |
| JP2016074676A (ja) | アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤 | |
| RU2004132856A (ru) | Фармацевтический препарат с модифицированным высвобождением | |
| DE69827853D1 (de) | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| JPH0228580B2 (https=) | ||
| HUT50325A (en) | Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient | |
| HU9303082D0 (en) | Process for production of 3,4-dihydro-2(1h)-quinolyne-derivatives with neuroprotective action and of pharmaceutical compositions containing them as medical agent | |
| DE69814089T2 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung |